Operating cash flow has been negative in every recent quarter, with free cash flow of -$78.2M in 2026Q3, and zero dividends or buybacks indicate all capital is retained to fund research operations.
Kymera Therapeutics, Inc. (KYMR) cash flow statement — 8-year operating, investing & financing cash flows
| Metric | TTM | Dec'25 | Dec'24 | Dec'23 | Dec'22 | Dec'21 | Dec'20 | Dec'19 | Dec'18 |
|---|
| Cash from Operations | -287.56M | -232.89M | -194.5M | -102.83M | -153.09M | -128.95M | 88.13M | 17.91M | -17.86M |
| Operating CF Margin % | - | -594.11% | -413.2% | -130.84% | -326.92% | -177.05% | 258.95% | 610.26% | - |
| Operating CF Growth % | -197.95% | -19.74% | -89.16% | 32.83% | -18.72% | -246.31% | 392.21% | 200.24% | - |
| Net Income | -349.47M | -311.35M | -223.86M | -146.96M | -154.81M | -100.22M | -45.59M | -41.25M | -21.47M |
| Depreciation & Amortization | 8.11M | 8.31M | 7.37M | 3.56M | 2.98M | 2.4M | 1.76M | 825K | 205K |
| Stock-Based Compensation | 68.23M | 59.9M | 55.01M | 43.12M | 35.48M | 24.97M | 5.19M | 1.2M | 648K |
| Deferred Taxes | 0 | 0 | 0 | 0 | 0 | 0 | 1.57M | 0 | 0 |
| Other Non-Cash Items | -8.71M | -5.02M | -9.06M | -11.8M | 889K | 5.83M | 332K | 54.34M | 443K |
| Working Capital Changes | -5.77M | 15.27M | -23.97M | 9.25M | -37.62M | -61.92M | 124.87M | 2.79M | 2.31M |
| Change in Receivables | 0 | 947K | 17.82M | -16.23M | -2.4M | 577K | -577K | 0 | -148K |
| Change in Inventory | 0 | 0 | 0 | 0 | 2.4M | 8.71M | 6.88M | 0 | 0 |
| Change in Payables | 6.42M | -1.97M | -307K | 0 | 253K | 54K | 990K | 0 | 824K |
| Cash from Investing | -415.56M | -521.06M | -404.08M | 139.89M | 20.52M | -99.83M | -422.59M | -16.49M | -1.36M |
| Capital Expenditures | -1.33M | -1.45M | -12.84M | -34.48M | -2.84M | -1.6M | -9.1M | -532K | -1.36M |
| CapEx % of Revenue | 1.3% | 3.7% | 27.27% | 43.87% | 6.06% | 2.19% | 26.73% | 18.13% | - |
| Acquisitions | 0 | 0 | 0 | 0 | -20.52M | 5.81M | 413.49M | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - | - |
| Other Investing | 4.78M | 8.88M | 13.98M | 174.37M | 20.52M | -5.81M | -413.49M | -15.95M | 0 |
| Cash from Financing | 963.97M | 990.71M | 608.85M | 4.19M | 153M | 250.28M | 289.26M | 34.91M | 52.93M |
| Debt Issued (Net) | -2.15M | -1.49M | -1.58M | -76K | -1.13M | -849K | -554K | -371K | -295K |
| Equity Issued (Net) | 965.69M | 992.21M | 596.62M | 0 | 149.82M | 243.11M | 289.65M | 0 | 53.23M |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | 425K | 0 | 13.81M | 4.27M | 4.3M | 8.02M | 162K | 35.28M | 0 |
| Net Change in Cash | 260.85M | 236.76M | 10.27M | 41.25M | 20.43M | 21.5M | -45.2M | 36.33M | 33.71M |
| Free Cash Flow | -288.89M | -234.34M | -207.34M | -137.31M | -155.92M | -130.54M | 79.03M | 17.37M | -19.22M |
| FCF Margin % | -282.61% | -597.81% | -440.47% | -174.71% | -332.98% | -179.24% | 232.22% | 592.13% | - |
| FCF Growth % | -25.49% | -13.02% | -51.01% | 11.94% | -19.44% | -265.17% | 354.92% | 190.39% | - |
| FCF per Share | -2.89 | -2.78 | -2.76 | -2.35 | -2.89 | -2.72 | 1.77 | 0.39 | -0.43 |
| FCF Conversion (FCF/Net Income) | 0.83x | 0.75x | 0.87x | 0.70x | 0.99x | 1.29x | -1.93x | -0.43x | 0.83x |
| Interest Paid | -19K | 0 | 0 | 162K | 0 | 0 | 0 | 46K | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Quick answers to the most common questions about buying KYMR stock.
Kymera Therapeutics, Inc. (KYMR) generated $-232.9M in net cash from operating activities in 2025. This reflects the cash generated directly from core business operations.
Kymera Therapeutics, Inc. (KYMR) reported negative free cash flow of $234.3M in 2025, indicating capital requirements exceeded cash from operations.
Kymera Therapeutics, Inc. (KYMR) spent $1.4M on capital expenditures in 2025. CapEx represents the cash invested in physical assets like property, plant, and equipment to maintain or grow the business.
Key Metrics
Top Statement Risk
Persistent operating cash burn
Metrics are mathematically derived from official filings.
Losses Paired With Cash Burn Pattern
According to reported figures, KYMR's operating cash flow has been negative in every one of the last nine quarters, with OCF/NI ratios ranging from 0.33 to 1.28, indicating that losses are being converted into cash outflows rather than being masked by non-cash charges.
Because net losses are largely matched by operating cash outflows, the earnings-quality question is less about accruals and more about the absolute size of the burn. The OCF/NI ratio above 1.0 in several quarters, such as 2026Q1 at 1.28, suggests working capital movements or timing effects temporarily amplified cash outflows beyond reported losses. Investors should monitor whether the ratio normalizes, as sustained OCF exceeding net loss would warrant further investigation into working capital drains.
Free Cash Flow Deficits Widen Into 2026
Based on KYMR's reported figures, free cash flow turned to -$89.3M in 2026Q1 from -$27.3M in 2025Q3, with the latest quarter at -$78.2M, showing that the cash deficit has persisted at a much larger scale than the 2024 levels.
FCF margins are deeply negative and not meaningful as a profitability gauge given the lumpy revenue base, but the absolute burn is the decisive metric. Capital expenditure is negligible, so nearly all of the deficit is operating in nature, consistent with clinical-stage research spending. The trend suggests the cash runway is shaped by operating cost discipline rather than capital allocation choices.
Working Capital Swings Drive Quarterly Volatility
As reported in financial statements, KYMR's working capital change swung from a $38.5M inflow in 2025Q3 to a $34.9M outflow in 2026Q1, with the latest quarter showing a $34.8M outflow, making quarterly cash conversion unusually volatile.
The magnitude of working capital swings relative to net loss suggests collaboration receivables and deferred revenue timing, rather than inventory or payables dynamics, are the primary drivers. Such swings make single-quarter operating cash flow a weak indicator of the underlying burn rate. Analysts should focus on trailing multi-quarter averages to avoid misreading timing effects as structural change.
No Shareholder Returns Amid Burn
According to SEC-reported cash flow data, KYMR recorded zero dividends and zero share repurchases across all ten quarters, with acquisition spending unavailable, indicating that all capital is retained to fund research operations.
The absence of distributions is consistent with a company in clinical development that must preserve liquidity against a persistent operating deficit. Stock-based compensation of roughly $14M to $19M per quarter is a non-cash cost that partially cushions reported cash burn, but it also implies ongoing dilution pressure. Future capital needs will likely depend on external financing, and investors should monitor the terms of any such raise.
Stock Compensation Flatters the Burn Picture
Based on reported figures, KYMR's stock-based compensation of $13.8M to $18.9M per quarter is added back in operating cash flow, meaning the cash burn would appear materially larger if equity pay were settled in cash.
Treating SBC as a non-cash add-back is standard, but it obscures the real economic cost borne by shareholders through dilution. Because the company has no positive free cash flow to offset it, the add-back effectively shifts burden from the income statement to the share count. The analytical concern is that the apparent cash discipline may partly reflect equity-funded compensation rather than sustainable operating efficiency.